+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Gynecological Cancer Drugs Market by Therapeutic Modality and Indication - Global Opportunity Analysis and Industry Forecast, 2017-2023

  • ID: 4612800
  • Report
  • December 2017
  • Region: Global
  • 188 pages
  • Allied Analytics LLP
1 of 3

Enquire about COVID-19 updates for this product.

Enquire Now
The global gynecological cancer drugs market size was valued at $9,269 million in 2016, and is expected to reach $16,107 million by 2023, growing at a CAGR of 8.1% from 2017 to 2023.

Cancer refers to a specific group of disorder, which leads to abnormal cell growth within any part of the body. Gynecological cancer refers to a group of cancers that affect the reproductive organs of a female, such as uterus, endometrium, ovary, peritoneum, fallopian tubes, vagina, vulva, cervix, and muscle & tissue supporting the uterus.

High incidence of gynecological cancers, rise in importance of targeted drug therapies, rise in investment from government, public & private organizations for the development of novel drugs to treat cancer, and increase in risk factors that lead to cancer drive the market growth. However, high cost of drug development and threat of failure & adverse effects of cancer drug therapy restrain the growth of this market. Conversely, advancement of cancer drug research and advent of personalized medicine approach are expected to provide numerous opportunities for market growth during the forecast period.

The report segments the market based on therapeutic modality, indication, and region. Based on therapeutic modality, the market is divided into chemotherapy, targeted therapy, and hormonal therapy. The indications segment is categorized into uterine cancer, ovarian cancer, vaginal & vulvar cancer, and cervical cancer. Geographically, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, Italy, UK, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

KEY BENEFITS FOR STAKEHOLDERS

The study provides an in-depth analysis of the market with current trends and future estimations to elucidate the imminent investment pockets.
It offers a quantitative analysis from 2016 to 2023, which is expected to enable the stakeholders to capitalize on prevailing market opportunities.
Analysis by therapeutic modality helps to understand the various types of treatment modalities for treatment of gynecological cancer patients.
Comprehensive analysis of all geographical regions is provided, which helps to determine the prevailing opportunities.
Key players are profiled and their strategies are analyzed thoroughly, which helps to understand competitive outlook of the global market.

KEY MARKET SEGMENTS

By Therapeutic Modality

Chemotherapy
Targeted Therapy
Hormonal Therapy

By Indication

Uterine Cancer
Ovarian Cancer
Vaginal & Vulvar Cancer
Cervical Cancer

By Region

North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA

LIST OF KEY PLAYERS PROFILED IN THE REPORT

Apotex Inc.
AstraZeneca Plc
Bristol-Myers Squibb Company
Eli Lilly and Company
F. Hoffmann-La Roche AG
GlaxoSmithKline plc
Merck & Co., Inc.
Novartis AG
Pfizer Inc.
Teva Pharmaceutical Industries Ltd.
Note: Product cover images may vary from those shown
2 of 3
CHAPTER 1 INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS FOR STAKEHOLDERS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2 EXECUTIVE SUMMARY
2.1. KEY FINDINGS OF THE STUDY
2.2. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.2.1. Top investment pockets
3.2.2. Top winning strategies, 2015-2017
3.2.2.1. Top Winning Strategies, By Year, 2014-2017*
3.2.2.2. Top Winning Strategies, By Development, 2014-2017* (%)
3.2.2.3. Top Winning Strategies, By Company, 2014-2017*
3.3. TOP PLAYER POSITIONING, 2016
3.4. MARKET DYNAMICS
3.4.1. Drivers
3.4.1.1. Surge in incidence of gynecological cancers
3.4.1.2. Growing importance of targeted drug therapies
3.4.1.3. Increase in investment from government, public, and private sector
3.4.2. Restraints
3.4.2.1. High cost of drug development and threat of failure
3.4.2.2. Adverse effects of cancer drug therapy
3.4.3. Opportunities
3.4.3.1. Advancement of cancer drugs research
3.4.3.2. Personalized medicine approach
3.5. CLINICAL TRIALS

CHAPTER 4 GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY
4.1. OVERVIEW
4.1.1. Market size and forecast
4.2. CHEMOTHERAPY
4.2.1. Key market trends growth factors and opportunities
4.2.2. Market size and forecast
4.3. TARGETED THERAPY
4.3.1. Key market trends growth factors and opportunities
4.3.2. Market size and forecast
4.4. HORMONAL THERAPY
4.4.1. Key market trends growth factors and opportunities
4.4.2. Market size and forecast

CHAPTER 5 GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION
5.1. OVERVIEW
5.1.1. Market size and forecast
5.2. UTERINE CANCER
5.2.1. Market size and forecast
5.3. OVARIAN CANCER
5.3.1. Market size and forecast
5.4. VAGINAL & VULVAR CANCER
5.4.1. Market size and forecast
5.5. CERVICAL CANCER
5.5.1. Market size and forecast

CHAPTER 6 GYNECOLOGICAL CANCER DRUGS MARKET, BY REGION
6.1. OVERVIEW
6.1.1. Market size and forecast
6.2. NORTH AMERICA
6.2.1. Key market trends growth factors & opportunities
6.2.2. Market size & forecast
6.2.2.1. U.S.
6.2.2.1.1. U.S. gynecological cancer drugs market by therapeutic modality
6.2.2.1.2. U.S. gynecological cancer drugs market by indication
6.2.2.2. Canada
6.2.2.2.1. Canada gynecological cancer drugs market by therapeutic modality
6.2.2.2.2. Canada gynecological cancer drugs market by indication
6.2.2.3. Mexico
6.2.2.3.1. Mexico gynecological cancer drugs market by therapeutic modality
6.2.2.3.2. Mexico gynecological cancer drugs market by indication
6.2.3. North America gynecological cancer drugs market by therapeutic modality
6.2.4. North America gynecological cancer drugs market by indication
6.3. EUROPE
6.3.1. Key market trends growth factors & opportunities
6.3.2. Market size & forecast
6.3.2.1. Germany
6.3.2.1.1. Germany gynecological cancer drugs market by therapeutic modality
6.3.2.1.2. Germany gynecological cancer drugs market by indication
6.3.2.2. France
6.3.2.2.1. France gynecological cancer drugs market by therapeutic modality
6.3.2.2.2. France gynecological cancer drugs market by indication
6.3.2.3. UK
6.3.2.3.1. UK gynecological cancer drugs market by therapeutic modality
6.3.2.3.2. UK gynecological cancer drugs market by indication
6.3.2.4. Italy
6.3.2.4.1. Italy gynecological cancer drugs market by therapeutic modality
6.3.2.4.2. Italy gynecological cancer drugs market by indication
6.3.2.5. Spain
6.3.2.5.1. Spain gynecological cancer drugs market by therapeutic modality
6.3.2.5.2. Spain gynecological cancer drugs market by indication
6.3.2.6. Rest of Europe
6.3.2.6.1. Rest of Europe gynecological cancer drugs market by therapeutic modality
6.3.2.6.2. Rest of Europe gynecological cancer drugs market by indication
6.3.3. Europe gynecological cancer drugs market by therapeutic modality
6.3.4. Europe gynecological cancer drugs market by indication
6.4. ASIA-PACIFIC
6.4.1. Key market trends growth factors & opportunities
6.4.2. Market size & forecast
6.4.2.1. Japan
6.4.2.1.1. Japan gynecological cancer drugs market by therapeutic modality
6.4.2.1.2. Japan gynecological cancer drugs market by indication
6.4.2.2. China
6.4.2.2.1. China gynecological cancer drugs market by therapeutic modality
6.4.2.2.2. China gynecological cancer drugs market by indication
6.4.2.3. India
6.4.2.3.1. INDIA gynecological cancer drugs market by therapeutic modality
6.4.2.3.2. INDIA gynecological cancer drugs market by indication
6.4.2.4. Australia
6.4.2.4.1. Australia gynecological cancer drugs market by therapeutic modality
6.4.2.4.2. Australia gynecological cancer drugs market by indication
6.4.2.5. South Korea
6.4.2.5.1. South Korea gynecological cancer drugs market by therapeutic modality
6.4.2.5.2. South Korea gynecological cancer drugs market by indication
6.4.2.6. Rest of Asia-Pacific
6.4.2.6.1. Rest of Asia-Pacific gynecological cancer drugs market by therapeutic modality
6.4.2.6.2. Rest of Asia-Pacific gynecological cancer drugs market by indication
6.4.3. Asia-Pacific gynecological cancer drugs market by therapeutic modality
6.4.4. Asia-Pacific gynecological cancer drugs market by indication
6.5. LAMEA
6.5.1. Key market trends growth factors & opportunities
6.5.2. Market size & forecast
6.5.2.1. Brazil
6.5.2.1.1. Brazil gynecological cancer drugs market by therapeutic modality
6.5.2.1.2. Brazil gynecological cancer drugs market by indication
6.5.2.2. South Africa
6.5.2.2.1. South Africa gynecological cancer drugs market by therapeutic modality
6.5.2.2.2. South Africa gynecological cancer drugs market by indication
6.5.2.3. Saudi Arabia
6.5.2.3.1. Saudi Arabia gynecological cancer drugs market by therapeutic modality
6.5.2.3.2. Saudi Arabia gynecological cancer drugs market by indication
6.5.2.4. Rest of LAMEA
6.5.2.4.1. Rest of LAMEA gynecological cancer drugs market by therapeutic modality
6.5.2.4.2. Rest of LAMEA gynecological cancer drugs market by indication
6.5.3. LAMEA gynecological cancer drugs market by therapeutic modality
6.5.4. LAMEA gynecological cancer drugs market by indication

CHAPTER 7 COMPANY PROFILES
7.1. APOTEX INC.
7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product portfolio
7.2. ASTRAZENECA PLC
7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product portfolio
7.2.5. Business performance
7.2.6. Key strategic moves and developments
7.3. BRISTOL-MYERS SQUIBB COMPANY
7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Product portfolio
7.3.5. Business performance
7.3.6. Key strategic moves and developments
7.4. ELI LILLY AND COMPANY
7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product portfolio
7.4.5. Business performance
7.5. F. HOFFMANN-LA ROCHE LTD
7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product portfolio
7.5.5. Business performance
7.5.6. Key strategic moves and developments
7.6. GLAXOSMITHKLINE PLC
7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product portfolio
7.6.5. Business performance
7.6.6. Key strategic moves and developments
7.7. MERCK & CO., INC.
7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product portfolio
7.7.5. Business performance
7.7.6. Key strategic moves and developments
7.8. NOVARTIS AG
7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product portfolio
7.8.5. Business performance
7.9. PFIZER INC
7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product portfolio
7.9.5. Business performance
7.9.6. Key strategic moves and developments
7.10. TEVA PHARMACEUTICAL INDUSTRIES LTD
7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product portfolio
7.10.5. Business performance
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...

Adroll
adroll